Davide Caruso

Davide Caruso

Auto-generated profile, based on publicly available information

Davide Caruso

Asl 3 Genovese Ospedale Padre Antero Micone , Genova

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2015 in OncoTargets and Therapy
Verified
Journal Article
Open access
FTFederica Tomao
Federica Tomao
APAnselmo Papa
Anselmo Papa
EZEleonora Zaccarelli
Eleonora Zaccarelli
LRLuigi Rossi
Luigi Rossi
DCDavide Caruso
Davide Caruso
STSilverio Tomao
Silverio Tomao
Breast cancer is a heterogeneous disease, encompassing a large number of entities showing different morphological features and having clinical behaviors. It has became apparent that this diversity may be justified by distinct patterns of genetic, epigenetic, and transcriptomic aberrations. The identification of gene-expression microarray-based characteristics has led to the identification of at least five breast cancer subgroups: luminal A, luminal B, normal breast-like, human epidermal growth factor receptor 2, and basal-like. Triple-negative breast cancer is a complex disease diagnosed by immunohistochemistry, and it is characterized by malignant cells not expressing estrogen receptors or progesterone receptors at all, and human epidermal growth factor receptor 2. Along with this knowledge, recent data show that triple-negative breast cancer has specific molecular features that could be possible targets for new biological targeted drugs. The aim of this article is to explore the use of new drugs in this particular setting, which is still associated with poor prognosis and high risk of distant recurrence and death.

1 December 2014 in OncoTargets and Therapy
Verified
Journal Article
Open access
STSilverio Tomao
Silverio Tomao
FTFederica Tomao
Federica Tomao
LRLuigi Rossi
Luigi Rossi
EZEleonora Zaccarelli
Eleonora Zaccarelli
DCDavide Caruso
Davide Caruso
APAnselmo Papa
Anselmo Papa
Standard treatment of cervical cancer (CC) consists of surgery in the early stages and of chemoradiation in locally advanced disease. Metastatic CC has a poor prognosis and is usually treated with palliative platinum-based chemotherapy. Current chemotherapeutic regimens are associated with significant adverse effects and only limited activity, making identification of active and tolerable novel targeted agents a high priority. Angiogenesis is a complex process that plays a crucial role in the development of many types of cancer. The dominant role of angiogenesis in CC seems to be directly related to human papillomavirus-related inhibition of p53 and stabilization of hypoxia-inducible factor-1α. Both of these mechanisms are able to increase expression of vascular endothelial growth factor (VEGF). Activation of VEGF promotes endothelial cell proliferation and migration, favoring formation of new blood vessels and increasing permeability of existing blood vessels. Since bevacizumab, a recombinant humanized monoclonal antibody binding to all isoforms of VEGF, has been demonstrated to significantly improve survival in gynecologic cancer, some recent clinical research has explored the possibility of using novel therapies directed toward inhibition of angiogenesis in CC too. Here we review the main results from studies concerning the use of antiangiogenic drugs that are being investigated for the treatment of CC.

13 October 2014 in Expert Opinion on Therapeutic Targets
Verified
Journal Article
Closed access
APAnselmo Papa
Anselmo Papa
DCDavide Caruso
Davide Caruso
STSilverio Tomao
Silverio Tomao
LRLuigi Rossi
Luigi Rossi
EZEleonora Zaccarelli
Eleonora Zaccarelli
FTFederica Tomao
Federica Tomao
Triple-negative breast cancer (TNBC) makes up about 10 - 20% of all breast cancers and the lack of hormone receptors and human epidermal growth factor receptor-2/Neu expression is responsible for poor prognosis, no targeted therapies and trouble in the clinical management. Tumor heterogeneity, also within the same tumor, is a major cause for this difficulty. Based on the introduction of new biological drugs against different kinds of tumor, many efforts have been made for classification of genetic alterations present in TNBC, leading to the identification of several oncogenes and tumor suppressor genes involved in breast cancer carcinogenesis. In this review we investigated the molecular alteration present in TNBC which could lead to the creation of new targeted therapies in the future, with the aim to counteract this disease in the most effective way. In this context some hormone receptors like G-protein-coupled receptor 30 and androgen receptors may be a fascinating area to investigate; also, angiogenesis, represented not only by the classical VEGF/VEGFR relationship, but also by other molecules, like semaphorins, fibroblast growth factor and heparin-binding-EGF-like, is a mechanism in which new developments are expected. In this perspective, one technique that may show promise is the gene therapy; in particular the gene transfer could correct abnormal genetic function in cancer cells.

11 October 2013 in Expert Opinion on Investigational Drugs
Verified
Journal Article
Closed access
FTFederica Tomao
Federica Tomao
APAnselmo Papa
Anselmo Papa
LRLuigi Rossi
Luigi Rossi
DCDavide Caruso
Davide Caruso
FZFederica Zoratto
Federica Zoratto
STSilverio Tomao
Silverio Tomao
Introduction: Ovarian cancer is the most lethal gynecological cancer, mainly because of the advanced stage of the disease at diagnosis, with recent research investigating novel targets and agents into the clinical practice, with the aim to improve prognosis and quality of life. Angiogenesis is a significant target for ovarian cancer therapy. Areas covered: Areas covered in this review include the most common molecular pathways of angiogenesis, which have provided novel targets for tailored therapy in ovarian cancer patients. These therapeutic strategies comprise monoclonal antibodies and tyrosine kinase inhibitors. These drugs have as molecular targets such as vascular endothelial growth factor (VEGF), VEGF receptor, platelet-derived growth factor, fibroblast growth factor, angiopoietin and Ephrin type-A receptor 2. Expert opinion: The expansion in understanding the molecular biology that characterizes cancer cells has led to the rapid development of new agents to target important pathways, but the heterogeneity of ovarian cancer biology indicates that there is no predominant defect. This review attempts to discuss progress till date in tackling a more general target applicable to ovarian cancer angiogenesis.

27 June 2014 in Tumor Biology
Verified
Journal Article
Closed access
PDF file
FTFederica Tomao
Federica Tomao
APAnselmo Papa
Anselmo Papa
GRGiuseppe Lo Russo
Giuseppe Lo Russo
SZSara Zuber
Sara Zuber
GSGian Paolo Spinelli
Gian Paolo Spinelli
STSilverio Tomao
Silverio Tomao

1 November 2013 in Cancer Management and Research
Verified
Journal Article
Open access
LRLuigi Rossi
Luigi Rossi
FVFoteini Vakiarou
Foteini Vakiarou
FZFederica Zoratto
Federica Zoratto
APAnselmo Papa
Anselmo Papa
LBLoredana Bianchi
Loredana Bianchi
APAlessandra Anna Prete
Alessandra Anna Prete
Peer reviewed article authored by (Rossi L, Vakiarou F, Zoratto F, Bianchi L, Papa A, Basso E, Verrico M, Lo Russo G, Evangelista S, Rinaldi G, Perrone-Congedi F, Spinelli GP, Stati V, Caruso D, Prete A, Tomao S). Read article or submit your manuscript for publishing.